News|Slideshows|June 15, 2022

Exercise Through the Ages: From Foraging to Sitting Still

Exercise began as foraging for survival for our hunter/gatherer forbears and is no less essential in our contemporary age of sitting and screen time. Take a quick trip through history.

Exercise has been integral to human life for millennia, evolving over 12 000 years from the early hunter/gatherer societies when survival depended on physical fitness.

Looking out from the 21st century it’s clear we didn’t shift from foraging for subsistence to sitting and screen time over night. Trace the evolution through this short slide show of 10 highlights from the journey.

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Related to this article

September 22nd, 2026

FDA Approves Sotatercept-csrk Label Update for Newly Diagnosed PAH

FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.

Intensive Blood Pressure Control May Lower Dementia Risk

September 1st, 2026

Intensive Blood Pressure Control in Primary Care May Lower Dementia Risk

A team-based blood pressure intervention delivered through primary care reduced dementia risk by 15% over 7 years.

August 28th, 2026

FDA Expands Tirzepatide Label for Cardiovascular Risk Reduction in Type 2 Diabetes

Tirzepatide gained an FDA cardiovascular indication after SURPASS-CVOT showed noninferiority to dulaglutide in high-risk adults.

August 27th, 2026

Physical Activity May Reduce Stroke and Mortality Risk in Persons With Atrial Fibrillation

Physical activity was associated with up to 22% lower mortality and 19% lower stroke risk in adults with and without atrial fibrillation in a large Norwegian cohort study.

October 2nd, 2026

Fezolinetant Linked to 2.6 Fewer Nighttime Awakenings in Women With Menopausal VMS

Real-world phase 4 data show fezolinetant eases menopausal hot flashes and improves sleep, cutting nighttime awakenings by 2.6 by week 12.

October 1st, 2026

5 FDA Decisions for Primary Care to Know from September 2026

September FDA news included updates in CKD and type 1 diabetes, major depressive disorder, insulin pump technology, alopecia areata, and more.

September 30th, 2026

Lebrikizumab Improves Hand and Foot Atopic Dermatitis in Phase 3b Trial

EADV 2026: Lebrikizumab improved hand and foot clearance, itch, and pain at 16 weeks versus placebo in a phase 3b atopic dermatitis trial.

September 30th, 2026

CagriSema Alters Food-Cue Responses, Reduces Organ Fat in New Analyses

EASD 2026: The combination of semaglutide/cagrilintide altered food-cue responses and showed a 22.4% estimated weight difference vs placebo; separate data found less organ fat in type 2 diabetes.